BIOCRYST PHARMACEUTICALS INC's ticker is BCRX and the CUSIP is 09058V103. A total of 104 filers reported holding BIOCRYST PHARMACEUTICALS INC in Q2 2018. The put-call ratio across all filers is 0.44 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,674,852 | -15.1% | 236,561 | 0.0% | 0.00% | 0.0% |
| Q2 2023 | $1,972,919 | 0.0% | 236,561 | 0.0% | 0.00% | 0.0% |
| Q1 2023 | $1,972,919 | -15.6% | 236,561 | +16.1% | 0.00% | 0.0% |
| Q4 2022 | $2,338,477 | -99.9% | 203,700 | -0.0% | 0.00% | 0.0% |
| Q3 2022 | $2,567,539,000 | +21.0% | 203,773 | +1.6% | 0.00% | 0.0% |
| Q2 2022 | $2,121,512,000 | -43.6% | 200,521 | -13.3% | 0.00% | -50.0% |
| Q1 2022 | $3,758,499,000 | +32.8% | 231,150 | +13.1% | 0.00% | +100.0% |
| Q4 2021 | $2,829,873,000 | +12.7% | 204,323 | +16.9% | 0.00% | 0.0% |
| Q3 2021 | $2,511,314,000 | -32.1% | 174,761 | -25.3% | 0.00% | -50.0% |
| Q2 2021 | $3,697,850,000 | +55.8% | 233,893 | +0.2% | 0.00% | +100.0% |
| Q1 2021 | $2,373,810,000 | +26.1% | 233,413 | -7.6% | 0.00% | 0.0% |
| Q4 2020 | $1,882,057,000 | -52.8% | 252,625 | -78.2% | 0.00% | -50.0% |
| Q3 2020 | $3,988,567,000 | -27.9% | 1,161,155 | 0.0% | 0.00% | -33.3% |
| Q2 2020 | $5,532,904,000 | +2279.0% | 1,161,155 | +898.5% | 0.00% | – |
| Q1 2020 | $232,570,000 | -47.2% | 116,285 | -8.9% | 0.00% | – |
| Q4 2019 | $440,468,000 | +108.5% | 127,672 | +73.1% | 0.00% | – |
| Q3 2019 | $211,276,000 | -15.5% | 73,744 | +11.8% | 0.00% | – |
| Q2 2019 | $249,981,000 | -49.8% | 65,958 | +7.9% | 0.00% | – |
| Q1 2019 | $497,801,000 | +28.4% | 61,155 | +27.3% | 0.00% | – |
| Q4 2018 | $387,594,000 | +5.8% | 48,029 | 0.0% | 0.00% | – |
| Q3 2018 | $366,462,000 | +33.2% | 48,029 | 0.0% | 0.00% | – |
| Q2 2018 | $275,206,000 | -4.2% | 48,029 | -20.2% | 0.00% | – |
| Q1 2018 | $287,225,000 | +38.7% | 60,215 | +42.7% | 0.00% | – |
| Q4 2017 | $207,129,000 | -6.3% | 42,185 | 0.0% | 0.00% | – |
| Q3 2017 | $221,049,000 | +0.0% | 42,185 | +6.1% | 0.00% | – |
| Q2 2017 | $220,971,000 | -43.6% | 39,743 | -14.8% | 0.00% | – |
| Q1 2017 | $392,020,000 | +326583.3% | 46,669 | +72.2% | 0.00% | – |
| Q3 2016 | $120,000 | +55.8% | 27,100 | 0.0% | 0.00% | – |
| Q2 2016 | $77,000 | 0.0% | 27,100 | 0.0% | 0.00% | – |
| Q1 2016 | $77,000 | -72.7% | 27,100 | -0.7% | 0.00% | – |
| Q4 2015 | $282,000 | -16.8% | 27,300 | -8.1% | 0.00% | – |
| Q3 2015 | $339,000 | -20.4% | 29,700 | +4.2% | 0.00% | – |
| Q2 2015 | $426,000 | +80.5% | 28,500 | +9.2% | 0.00% | – |
| Q1 2015 | $236,000 | -21.3% | 26,100 | +5.7% | 0.00% | – |
| Q4 2014 | $300,000 | +42.2% | 24,700 | +14.4% | 0.00% | – |
| Q3 2014 | $211,000 | -19.2% | 21,600 | +5.4% | 0.00% | – |
| Q2 2014 | $261,000 | +20.3% | 20,500 | 0.0% | 0.00% | – |
| Q1 2014 | $217,000 | +39.1% | 20,500 | 0.0% | 0.00% | – |
| Q4 2013 | $156,000 | – | 20,500 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| RP Management, LLC | 3,846,154 | $27,230,770 | 26.28% |
| Prosight Management, LP | 2,408,135 | $17,049,596 | 5.40% |
| Kynam Capital Management, LP | 3,133,193 | $22,183,006 | 3.63% |
| Saturn V Capital Management LP | 982,458 | $6,955,803 | 2.91% |
| AlphaCentric Advisors LLC | 649,000 | $4,594,920 | 2.61% |
| TANG CAPITAL MANAGEMENT LLC | 1,800,000 | $12,744,000 | 1.80% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 791,671 | $5,605,031 | 1.70% |
| Eversept Partners, LP | 2,479,103 | $17,552,049 | 1.48% |
| DAFNA Capital Management LLC | 652,000 | $4,616,160 | 1.44% |
| Avoro Capital Advisors LLC | 11,550,000 | $81,774,000 | 1.28% |